GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » 3-Year EPS without NRI Growth Rate

Verastem (Verastem) 3-Year EPS without NRI Growth Rate : 8.60% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Verastem 3-Year EPS without NRI Growth Rate?

Verastem's EPS without NRI for the three months ended in Dec. 2023 was $-1.03.

During the past 3 years, the average EPS without NRI Growth Rate was 8.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 31.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Verastem was 42.50% per year. The lowest was -45.20% per year. And the median was 6.95% per year.


Competitive Comparison of Verastem's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Verastem's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Verastem's 3-Year EPS without NRI Growth Rate falls into.



Verastem 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Verastem  (NAS:VSTM) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Verastem 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Verastem's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem (Verastem) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Executives
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Daniel Calkins officer: Vice President of Finance C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Dan Paterson officer: Chief Operating Officer 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Karin Anna Tollefson director C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur director 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Verastem (Verastem) Headlines

From GuruFocus

Verastem Oncology Announces Reverse Stock Split

By Business Wire Business Wire 05-31-2023

Verastem Oncology to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 05-01-2023

Verastem Oncology Appoints Rob Gagnon to Board of Directors

By Business Wire Business Wire 12-15-2022